Journal
CELL STEM CELL
Volume 1, Issue 5, Pages 497-501Publisher
CELL PRESS
DOI: 10.1016/j.stem.2007.10.005
Keywords
-
Categories
Ask authors/readers for more resources
Current measures of anticancer drug efficacy reflect bulk cell killing and are poorly suited to detect activity against cancer stem cells (CSCs), which sustain tumor growth. The CSC paradigm necessitates a reexamination of methodologies used to evaluate clinical efficacy of anticancer therapies, as well as strategies employed during preclinical drug development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available